Navigation Links
CryoLife Responds to Inaccurate Assertions from Plaintiff's Attorney

ATLANTA, Jan. 11 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY), a biomaterials, medical device and tissue processing company, announced today that it has been notified that a lawsuit will be filed against it in the Superior Court of Cobb County, Georgia relating to a meniscal allograft.

The lawsuit concerns an individual who contracted an infection following a transplant of a meniscal allograft in December 2006. Meniscal transplants are commonly used for patients with significant damage to the knee, who have already undergone several previous knee operations. A meniscal transplant is often recommended as the last resort before total knee replacement surgery. When a meniscal transplant is contemplated, it is routine medical procedure for the patient to be informed of the risks of transplant surgery, including the risk of infection from the transplanted tissue.

After receiving notice of the individual's infection, CryoLife conducted an immediate and thorough investigation of the manner in which the transplanted tissue was recovered and handled. As a result of this investigation, CryoLife believes that it handled the tissue in accordance with its procedures and in accordance with all applicable industry standards and regulatory requirements. Shortly after the infection was discovered, CryoLife notified the FDA of the incident, as it was required to do.

"We regret that this recipient experienced a problem following implant of our aseptically-processed tissue. We wish him the best; however, it is our understanding that his knee function was severely compromised prior to his meniscal transplant. Regrettably, the lawyers representing this individual have chosen to make untrue public statements against our company and our tissue processing services in an effort to force us into a monetary settlement of the case," stated Ashley Lee, executive vice president, chief operating officer and chief financial officer of CryoLife. "We feel it is important that we address these statements."

"We are confident that we followed industry standard and FDA practices and policies fully in processing this tissue and in notifying the proper authorities after learning of the infection. We intend to vigorously defend against this lawsuit and believe that we have adequate insurance coverage for this particular case."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlue(R) Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'Brien(R) stentless porcine heart valve, which is CE marked for distribution within the European Community. For additional information about CryoLife please visit

Statements made in this press release that look forward in time or that express management's beliefs, expectations or hopes are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include those regarding the potential outcome of the litigation described above. These future events may not occur as and when expected, if at all, and, together with the Company's business, are subject to various risks and uncertainties. These risks and uncertainties include the uncertainties surrounding the trial of any litigation, the expenses associated with that litigation and the risk of an adverse judgment at trial, as well as risk factors detailed in CryoLife's Securities and Exchange Commission filings, including CryoLife's Form 10-K filing for the year ended December 31, 2006, its most recent Form 10-Q, and the Company's other SEC filings. The Company does not undertake to update its forward-looking statements.

For additional information about the company, visit CryoLife's Web site:

Media Contacts:

D. Ashley Lee Jim McCarthy

Executive Vice President, Chief Financial McCarthy Communications

Officer and Chief Operating Officer

Phone: 770-419-3355 Phone: 202-333-8810

SOURCE CryoLife, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. CryoLife Announces Record Preservation Services and Product Revenues for 2007
2. CryoLife to Present at OneMedPlace Finance Forum
3. CryoLife to Present at 19th Annual Piper Jaffray Health Care Conference in New York
4. CryoLife to Conduct Annual Cardiac Surgery Fellows Allograft Symposium
5. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. CryoLife to Present at Bear Stearns Healthcare and First Albany Capitals Regenerative Technologies Conferences in New York
8. CryoLife Names Philip Theodore as Vice President, General Counsel
9. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
10. Michigan Catholic Conference Responds to Formation of Embryonic Stem Cell Research Ballot Committee
11. Updated Drug Development Scrip Report Responds to the Pharma Industrys Major Changes
Post Your Comments:
(Date:10/13/2015)... ... , ... Proove Biosciences, a commercial and research leader ... Keck Medicine of the University of Southern California (USC) Pain Center to ... Research Clinical Objectives Linking Genotypic and Phenotypic Association with Pain Outcomes) is one ...
(Date:10/12/2015)... Ga. , Oct.12, 2015  MiMedx Group, Inc. ... utilizing human amniotic tissue and patent-protected processes to develop ... Care, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic, and the ... complaint which had been filed against the Company has ... H. Petit , Chairman and CEO, stated, "As we ...
(Date:10/12/2015)... 12, 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:  AEZS) ... in developing and commercializing novel treatments in oncology, endocrinology ... Dennis Turpin , the Company,s former Senior Vice President, ... Quebec City office.  ... Executive Officer of the Company commented, "After a comprehensive ...
(Date:10/12/2015)... (PRWEB) , ... October 12, 2015 , ... ... today that Dr. Srini Srinivasan, has joined the firm as a Premier Expert ... professional stature enable them to bring extraordinary value to the company's clients. ...
Breaking Biology Technology:
(Date:10/1/2015)... Oct. 1, 2015  Biometrics includes diverse set ... body characteristics, such as fingerprints, eye retinas, facial ... of biometrics technology has been constantly increasing in ... five years. In addition to the most prominent ... recognition, other means of biometric authentication are rapidly ...
(Date:9/30/2015)... NEW YORK , Sept. 30, 2015  The global ... $10,025 billion for 2015. So says a new report on ... and diabetes management segment dominate the market, followed by continuous ... research publisher. Kalorama reports on the market for these products in ... .  ...
(Date:9/28/2015)... , Sept. 28, 2015 CLEAR, ... that its expedited traveler service is coming ... transforms travel, bringing a frictionless experience, serious ... "CLEAR offers our travelers an ... service," said Jim Smith , Executive ...
Breaking Biology News(10 mins):